IMR Press / FBL / Volume 6 / Issue 4 / DOI: 10.2741/opler

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Abnormal phospholipid metabolism in schizophrenia: evidence from epidemiological findings, clinical observations, and preliminary clinical trials
Show Less
1 Joseph L. Mailman School of Public Health, Columbia University, New York, New York 10032
2 Columbia University College of Physicians and Surgeons, New York, New York 10032
3 New York State Office of Mental Health, 1500 Waters Place, Bronx, New York 10461

Academic Editor: Liesl Jones

Front. Biosci. (Landmark Ed) 2001, 6(4), 61–65;
Published: 1 September 2001
(This article belongs to the Special Issue Schizophrenia, pathology and treatment)

Both epidemiological findings and clinical observations and have shaped our thinking as regards to the neuropathology of schizophrenia. Epidemiological findings implicating environmental risk factors, including maternal dietary deficiency and urban birth place, suggest schizophrenia is a developmental disorder, whereas clinical observations gave rise to the "dopamine hypothesis." Epidemiological findings lead to complex multifactorial models, while clinical observations lead to more readily to testable, but not necessarily generalizable, hypotheses. Points where findings from these different approaches converge may provide us with new insights and points of departure. In this paper, clinical observations and epidemiological findings are presented which suggests that a subgroup of schizophrenics have abnormalities in phospholipid metabolism. Preliminary clinical trials involving administration of omega-3 fatty acids thus far appear to support this hypothesis.

Back to top